Omeprazol Hikma

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Omeprazol Hikma

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule or tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic

What is Omeprazole and What Class of Medicine is It?

Omeprazol Hikma is a pharmaceutical preparation centered on the active ingredient, omeprazole, a compound recognized as a substituted benzimidazole. It is officially classified as a Proton Pump Inhibitor (PPI), which places it within the group of potent antisecretory agents. Omeprazole was the first drug in the PPI class to receive broad clinical acceptance, establishing a new therapeutic standard supported by extensive pharmacological studies. The conclusion from this classification is that the medicine acts directly to provide comprehensive control over the amount of acid the stomach produces.


Composition and Delivery: Why is Omeprazole Formulated as a Delayed-Release Capsule?

Omeprazol Hikma is a single-ingredient product administered via the oral route, packaged specifically as a delayed-release capsule or tablet containing enteric-coated granules. This precise dosage form is necessary because the omeprazole compound is highly acid-labile and would be destroyed by the acid in the stomach lumen before it could be absorbed. The specialized coating ensures the active ingredient passes safely through the highly acidic stomach, allowing it to release and activate only in the less acidic environment of the small intestine. This delivery strategy is universally applied to omeprazole products and is key to ensuring the drug performs its intended function effectively.


General Purpose: How Does Omeprazole Affect Stomach Acid?

The primary function of this medication is the prolonged and comprehensive reduction of gastric acid secretion. This benefit is achieved by the drug’s core mechanism of effect: it causes irreversible inhibition of the H^+/K^+ ATPase enzyme system, commonly known as the gastric proton pump. By disabling this final common pathway for acid production, Omeprazole provides sustained control over the overall acidity level in the stomach, which offers relief in general use scenarios, such as mitigating the discomfort associated with excessive gastric acid production. This effect has been clinically recognized for providing effective relief of symptoms related to acid hypersecretion.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information
Advertisements

What side effects are possible with Omeprazol Hikma?

Possible side effects and safety information

The official safety profile for omeprazole is structured around adverse reactions classified by frequency, the body systems affected, and safety concerns related to the duration of use.

Classification Examples of Officially Documented Adverse Reactions
Common Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence are the most frequently reported adverse reactions, typically categorized as Common in regulatory documents.
Uncommon Reactions reported with lower incidence include dizziness, paresthesia (tingling sensation), insomnia, and various skin reactions such as dermatitis, pruritus, rash, and urticaria.
Serious Adverse Reactions Infrequent but clinically significant events include severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), acute interstitial nephritis (kidney inflammation), hepatic failure, and severe hypersensitivity reactions like anaphylaxis.

Safety Patterns Related to Exposure

Safety data explicitly note risks associated with prolonged use. An increased risk for osteoporosis-related fractures (hip, wrist, or spine) has been reported, particularly with high-dose and long-term therapy, defined as a year or longer. The official labeling also documents the potential for hypomagnesemia (low magnesium) and Vitamin B12 deficiency with extended, long-term daily administration. Furthermore, the use of omeprazole may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD).

Population-Specific and General Constraints

The safety profile includes specific considerations for certain patient groups. Dose reduction may be necessary for patients with known hepatic impairment due to altered drug clearance. In general, the medicine should not be used in individuals with a known hypersensitivity to omeprazole or other substituted benzimidazoles. Symptomatic relief experienced while taking the medicine does not preclude the presence of an underlying gastric malignancy, as stated in regulatory prescribing information.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding Omeprazol Hikma overdose is based on official government regulatory documents. If an overdose is suspected, immediate medical attention is required.

Documented Overdose Presentations

Symptoms reported in regulatory documents following the use of high doses of omeprazole are typically not life-threatening but necessitate prompt evaluation. The documented clinical manifestations observed in these situations include a cluster of non-specific symptoms affecting the digestive and nervous systems:

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.
  • Neurological: Headache, drowsiness (somnolence), confusion.
  • Other: Flushing and a fast heart rate (tachycardia).

Reported doses associated with these symptoms range up to 2,400 mg in adults and up to 270 mg in a 13-year-old patient. Despite these high exposures, the official classification notes that overdose is generally not life-threatening.

Required Emergency Action

There is no specific antidote for omeprazole overdose. Treatment involves supportive measures to manage the symptoms that appear. Because clinical data on overdose is limited, individuals are officially instructed to:

Seek immediate medical attention by calling Poison Control or going to the nearest emergency room right away if too much Omeprazol Hikma is taken. This instruction is critical even if the individual has not yet experienced any symptoms.

Advertisements

Therapeutic Uses of Omeprazol Hikma

Quick Facts

  • Targeted Conditions: Symptomatic relief for certain conditions related to excess stomach acid.
  • Key Uses: Management of gastroesophageal reflux disease (GERD), healing of ulcers in the stomach and duodenum, and addressing erosive esophagitis.
  • Combination Use: Utilized with other agents for the treatment of Helicobacter pylori infection.

Omeprazol Hikma is used to address various acid-related gastrointestinal conditions. Its primary therapeutic domains involve the management of symptoms associated with gastroesophageal reflux disease (GERD), where stomach contents move back into the esophagus. The treatment is also applied to promote healing of duodenal ulcers and gastric ulcers that may be caused by excess acid production or other factors.

The medication may contribute to the resolution of erosive esophagitis, a condition where the esophageal lining experiences tissue damage due to acid. Furthermore, it is utilized in combination with suitable antibiotics to treat Helicobacter pylori infection, which is often associated with peptic ulcer recurrence. For rare conditions characterized by excessive gastric acid, such as Zollinger-Ellison syndrome, this agent is considered as a management option. Patients should consult their healthcare provider for guidance tailored to their condition.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

This section describes the officially documented population eligibility rules for Omeprazol Hikma, strictly based on government regulatory labeling.

Eligibility Entity
Populations for Whom Use is Allowed
Adults (General Population); Geriatric patients (no routine dose adjustment).
Pediatric patients ge 1 year and ge 10 kg for GERD; ge 4 years for H. pylori eradication.
Populations for Whom Use is Contraindicated
Known Hypersensitivity to omeprazole or substituted benzimidazoles (chemical class).
Concomitant use with the antiretroviral drug nelfinavir.
Patients with rare hereditary problems like fructose intolerance (due to excipients).
Conditional Use or Restriction
Hepatic Impairment: Use requires caution, and a dose adjustment may be considered due to changes in metabolism.
Suspected Gastric Malignancy: Must be excluded before starting therapy, as symptom relief does not rule out the disease.
Use Not Established: Safety and efficacy have not been established in children under 1 year of age or those weighing < 10 kg.
Physiological Status
Pregnancy and Lactation: Use is generally permitted during both pregnancy and breastfeeding.
Advertisements

What should I know about interactions with other medicines?

Omeprazol Hikma has officially documented interaction patterns that are primarily driven by two pharmacokinetic effects: its potent inhibition of the CYP2C19 enzyme and its strong ability to suppress gastric acid. These effects determine the mandatory restrictions and warnings for co-administration with other medicines and substances.

Interaction Type Interacting Substance Official Regulatory Outcome
Contraindication Nelfinavir, Rilpivirine Prohibited for co-administration.
Metabolic (CYP2C19) Clopidogrel Diminishes anti-platelet activity.
Exposure Increase Cilostazol, Digoxin Increased systemic exposure or bioavailability.
Exposure Decrease Atazanavir, Ketoconazole Reduced plasma concentration due to pH increase.

Omeprazole affects the metabolism of CYP2C19 substrates, including diazepam and warfarin, by prolonging their elimination. Because the drug raises gastric pH, it also reduces the absorption of cyanocobalamin ( Vitamin B12) and other acid-sensitive compounds. Administration also carries a procedural constraint: omeprazole must be stopped for 5 to 14 days prior to Chromogranin A (CgA) testing to avoid interference with diagnostic results. Co-administration of the herbal product St. John's Wort or rifampin is officially avoided due to a potential reduction in omeprazole concentration. Population-specific considerations note that patients with hepatic impairment may have a heightened risk of interaction due to slower clearance.

Advertisements

Mechanism of Action

The Molecular Blockade of the Gastric Proton Pump

Omeprazol Hikma acts through a specific sequence of molecular events, focusing on inhibiting the enzyme responsible for the final step of gastric acid production. The drug's primary action is the irreversible inhibition of the H^+ K^+ ATPase enzyme, known as the gastric proton pump. Omeprazole, after activation, forms a covalent bond with this enzyme in the parietal cells, physically blocking the pump. This molecular blockade suppresses the final step of acid secretion, resulting in a substantial reduction of acid output, irrespective of upstream stimulatory signals such as Histamine or Gastrin.

Acid-Dependent Activation and Sustained Effect

Omeprazole functions as an acid-activated prodrug; it requires the extremely low pH environment within the acid-secreting canaliculi to chemically transform into its active inhibitory species. This mechanism ensures that the drug's inhibitory effect is highly selective to the site of acid production. The duration of the drug's action is defined by this irreversible mechanism; acid secretion can only be restored when the parietal cell synthesizes and inserts new proton pump units into its membrane. This dependence on cellular turnover leads to a sustained reduction in gastric acidity that extends beyond the drug's plasma half-life.

Advertisements

Dosage and Administration Information

How to Use Omeprazole

This section outlines usage instructions for omeprazole. It is not intended as medical advice.

Omeprazole is available in various dosage forms, including Delayed-Release Capsules/Tablets for oral use and Powder for Solution for intravenous (IV) infusion.

Administration and Dosing Rules

Guideline Instruction
Timing Take oral doses before a meal, typically in the morning.
Frequency Most regimens require dosing once daily; some high-dose or combination therapies require twice or three times daily.
Dose Form Handling Swallow capsules or tablets whole. The delayed-release formulation must not be crushed or chewed.
Special Preparation If a patient cannot swallow the capsule whole, the pellets may be mixed with a small amount of applesauce or acidic fluid (e.g., non-carbonated water or fruit juice) and swallowed immediately.

Special Procedural Conditions

Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not take extra or double doses.

IV Infusion: The IV powder must be reconstituted and administered as a slow infusion, typically over 20 to 30 minutes.

Course Duration: Non-prescription (OTC) use is limited to a 14-day consecutive course, which must not be repeated within a 4-month period without a healthcare provider's direction. Prescribed treatment courses vary by condition but are defined (e.g., 4 to 8 weeks for acute conditions).

Age-Specific: Dosing for children is weight-based and determined by a healthcare provider; no general dose adjustment is required for geriatric patients based on age alone.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Omeprazol Hikma

Research Evidence for Acid-Related Conditions

This section summarizes the structure of clinical trials and meta-analyses that were studied for conditions such as gastroesophageal reflux disease (GERD) and erosive damage to the esophagus. Studies included short-term randomized controlled trials (RCTs) that examined patient-reported outcomes describing discomfort, alongside objective measurements of physical healing using endoscopy. The research was primarily conducted in general adult populations. Findings describe patterns observed in these short-term studies, focusing on changes measured during the few weeks of the study period. What remains uncertain is the long-term characterization of outcomes regarding symptom patterns across all research. Follow-up durations were limited in the most rigorous controlled trials.

Research on Healing Duodenal and Gastric Ulcers

Research examined conditions associated with acute episodes of ulceration. Short-term RCTs were utilized in research exploring the time required for ulcer healing and outcomes related to physical discomfort. These trials monitored ulcer healing rates and assessed the time required for endoscopic confirmation of recovery. Findings describe patterns observed in the studies, where studies reported how symptoms evolved in the observed populations over defined, short time intervals. There is limited information for long-term outcomes regarding the frequency of ulcer recurrence independent of the presence of H. pylori.

Evidence as a Component of H. pylori Treatment

Combination therapy trials were evaluated as one component to assess bacterial eradication rates and the frequency of ulcer recurrence in patients with Helicobacter pylori infection. Research monitored laboratory confirmation of H. pylori eradication status (via testing) and assessed the rate of peptic lesion recurrence. Studies reported measurements related to how eradication rates were observed over short treatment periods. Measurements of eradication rate varied across different combination protocols when assessed in varying geographic regions.

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, with a substantial amount of evidence focusing primarily on short-term symptom patterns and healing rates. There is limited information for long-term data regarding outcomes following sustained use over many years. Data for certain populations remain limited, including those with multiple concurrent conditions. Comparative evidence remains limited for many older adult subgroups. Research is ongoing to address these gaps and provide further insight.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Omeprazol Hikma (FAQ)


Q: Is Omeprazol Hikma the same type of medicine as Tums or Rennie?

A: No, Omeprazole is classified as a Proton Pump Inhibitor (PPI), a type of medicine that reduces the amount of acid the stomach produces.

Antacids like Tums or Rennie belong to a different drug class. They work by neutralizing the acid that is already in your stomach, which offers temporary relief rather than sustained production control.


Q: What health problems is Omeprazol Hikma most commonly prescribed for?

A: Official regulatory documents indicate that omeprazole is used for several acid-related conditions. These include treating symptoms of Gastroesophageal Reflux Disease (GERD) and promoting the healing of erosive damage to the esophagus.

It is also prescribed for the short-term treatment of duodenal and gastric ulcers and is used as part of combination therapy for the eradication of H. pylori bacterial infection.


Q: How quickly should I expect to feel better after starting Omeprazol Hikma?

A: Omeprazole is not intended to provide immediate relief for heartburn symptoms. Some people may not feel the full effect of the medicine until they have been taking it for several days, as reported in official product information.

Individual response times may vary, but the drug is generally effective after consistent use.


Q: Are there any long-term effects associated with taking Omeprazol Hikma for several months?

A: Official safety data has reported certain risks associated with prolonged use, typically defined as one year or longer. These include an increased risk for osteoporosis-related fractures of the hip, wrist, or spine.

Extended, long-term use has also been associated with the potential for developing low levels of magnesium (hypomagnesemia) and Vitamin B12 deficiency.


Q: Can Omeprazol Hikma cause diarrhea or stomach upset?

A: Yes, regulatory documents list several gastrointestinal issues as Common adverse reactions. These frequently reported side effects include diarrhea, abdominal pain, flatulence, and nausea or vomiting.


Q: Does alcohol consumption affect how Omeprazol Hikma works?

A: Regulatory warnings typically advise caution regarding concurrent use of alcohol. Alcohol consumption may sometimes worsen the underlying acid reflux symptoms, which is a factor to consider while taking the medicine.


Q: Why do doctors recommend stopping this medicine after a certain period of time?

A: The non-prescription (OTC) use of omeprazole is officially limited to a 14-day consecutive course. This course should not be repeated within a 4-month period without a professional medical assessment.

This limit is specified in official prescribing information due to the potential for certain risks that increase with continuous, high-dose use over extended periods.


Q: Can you take Omeprazol Hikma if you have kidney disease?

A: Official regulatory information primarily addresses patients with liver impairment. However, post-marketing safety data has been associated with reports of acute interstitial nephritis (kidney inflammation) during omeprazole use.

Because omeprazole has been associated with these reports, using it when kidney problems are present is a consideration that requires professional assessment.


Q: How does Omeprazol Hikma help with stomach ulcers?

A: The medication treats stomach and duodenal ulcers by providing a sustained and profound reduction of gastric acid secretion.

By reducing the amount of acid, omeprazole creates a stable, low-acid environment within the stomach and intestines that supports the healing of damaged ulcer tissue.


Q: Do generic versions of Omeprazol work the same as the Hikma brand?

A: According to drug regulatory authorities, all generic drugs must be demonstrated to be bioequivalent to the brand-name version.

This means that generic omeprazole is required to contain the same active ingredient and demonstrate that it is absorbed and works in the body in a manner similar to the brand-name product.


Q: Does Omeprazol Hikma affect my body's absorption of calcium?

A: The official safety profile reports an increased risk for osteoporosis-related fractures (weakened bones), especially with long-term therapy.

While this risk is known, the mechanism is complex and may involve changes to mineral absorption, which is a factor to consider during extended use.


Q: Can Omeprazol Hikma cause changes in mood or anxiety?

A: The official safety profile reports a few effects related to the central nervous system. Specifically, insomnia (difficulty sleeping) is officially listed as an Uncommon adverse reaction.

Mood changes or anxiety are not commonly listed as separate, frequently reported side effects in regulatory documents.


Q: Can Omeprazol Hikma be taken with antacids, and if so, when?

A: Yes, official administration guidelines confirm that antacids may be used concomitantly (at the same time) with the delayed-release omeprazole capsules or tablets.


Q: Does Omeprazol Hikma interact with herbal supplements or vitamins?

A: Yes, official documents warn that omeprazole interacts with certain herbal products, such as St. John's Wort.

Additionally, because the medicine raises the stomach's pH level, it can reduce the absorption of some acid-sensitive compounds, including Vitamin B12, which is a consideration during long-term use.


Q: Does Omeprazol Hikma have a risk of rebound acid production when stopped?

A: Regulatory labels do not use the specific term 'rebound acid production.' However, if treatment is stopped, it is common for the original heartburn symptoms to return or recur.

The recurrence of symptoms is consistent with the drug’s design as a short-term treatment.


Q: What do people mean when they say this medicine is for 'acid reflux'?

A: 'Acid reflux' is the common, everyday term used to describe the symptoms of Gastroesophageal Reflux Disease (GERD). This is a condition where stomach acid frequently flows back up into the esophagus (the tube connecting your mouth and stomach).

Omeprazole is indicated to help control and reduce the severity of these symptoms.


Q: Is it normal to feel a change in taste while taking Omeprazol Hikma?

A: Yes, official regulatory documents list taste disturbance in the adverse reactions section. This means that changes in how things taste have been reported by patients during the clinical use of omeprazole.


Q: Can Omeprazol Hikma be taken by people with diabetes?

A: Regulatory documents do not list diabetes as a specific contraindication or warning. However, individuals managing diabetes with other medications should ensure all drug interactions are professionally reviewed before starting omeprazole.


Q: Why do some people experience headaches when they first start taking this medicine?

A: Headache is officially listed in regulatory documents as a Common adverse reaction, meaning it is one of the more frequently reported side effects.

While the precise underlying reason is generally not detailed in patient information, it is a recognized and expected temporary occurrence for some people starting the medication.


Q: What are the signs that Omeprazol Hikma is starting to work for my reflux?

A: According to official information regarding its indications, the signs that omeprazole is working include relief from the primary symptoms of GERD.

This may manifest as a reduction in the severity or frequency of heartburn, a decrease in difficulty swallowing, and an improvement in persistent cough associated with the condition.


Q: Are there special warnings for people with heart conditions using Omeprazol Hikma?

A: Official regulatory warnings exist regarding certain interactions that are relevant to heart patients.

Omeprazole may diminish the activity of the anti-platelet drug Clopidogrel and can increase the systemic exposure of Digoxin. The potential for these interactions underscores the importance of a professional review of all concurrent medications.

Advertisements

How should Omeprazol Hikma be stored and disposed of?

How to Store and Dispose of Omeprazol Hikma?

Omeprazol Hikma must be stored according to regulatory requirements to preserve the integrity of the delayed-release capsules.

Storage Conditions

Store the capsules at Controlled Room Temperature, defined as 20 C to 25 C. The medication must be protected from light and moisture and should be kept in the original container, which must be tightly closed.

  • Child Safety: Keep the product out of the sight and reach of children.
  • Stability: If supplied in bottles, any product remaining after 100 days from first opening must be discarded.

Disposal Instructions

Unused or expired Omeprazol Hikma must be disposed of in accordance with local regulations. It is recommended to utilize community drug take-back programs. If no program is available, follow standard instructions for disposal in household trash, which involves mixing the medicine with an undesirable substance before sealing and discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omeprazol Hikma found in:

A-Z Index: